SavedAdd your journal

Journals / International Journal of Innovative Research and Reviews / 2023 / Cilt: 7 Sayı: 1

Overview of Glioblastoma: Current Drugs and Novel Therapy Trends

Umut AKÇAKOCA
Kaan KÜÇÜKOĞLU
Pages
27–37
Publication Date
2023-07-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, the characteristics of glioblastoma multiforme (GBM), its incidence, genetic pathogenesis, risk factors, treatment options and drugs used in chemotherapy, difficulties encountered in treatment, novel therapies for GBM and challenges and future directions are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor.
📊
Key Findings & Data:GBM, a very aggressive tumor, has a low survival rate and currently has no curative treatment.
💡
Conclusion & Impact:In this paper, the characteristics of glioblastoma multiforme (GBM), its incidence, genetic pathogenesis, risk factors, treatment options and drugs used in chemotherapy, difficulties encountered in treatment, novel therapies for GBM and challenges and future directions are discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glioblastoma · Therapy · Chemotherapy

Abstract

Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. GBM, a very aggressive tumor, has a low survival rate and currently has no curative treatment. ATRX, TERT, TP53 mutations, loss of PTEN function, and EGFR and WT1 have been found to play a role in the genetic pathogenesis of GBM. It has been determined that ionizing radiation, obesity, some metals and chemicals, pesticides, TNF-α, IL-1 and IL-6 are risk factors of GBM. In GBM treatment, surgery, radiotherapy and chemotherapy are usually combined. Temozolomide, carmustine, irinotecan and bevacizumab are the most important anticancer agents used in chemotherapy for GBM therapy. Targeted molecular (precision) therapies, targeting DNA damage response pathways, targeting tumor metabolism, immunotherapies, and viral therapies are novel treatment options being studied for the treatment of GBM. In this paper, the characteristics of glioblastoma multiforme (GBM), its incidence, genetic pathogenesis, risk factors, treatment options and drugs used in chemotherapy, difficulties encountered in treatment, novel therapies for GBM and challenges and future directions are discussed.

🔖

Cite This Article

AKÇAKOCA, U., KÜÇÜKOĞLU, K. (2023). Overview of Glioblastoma: Current Drugs and Novel Therapy Trends. International Journal of Innovative Research and Reviews, Cilt: 7 Sayı: 1, 27–37. https://ajindex.com/articles/952332

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. 1]McKinney PA. Brain tumours: incidence, survival, and aetiology. Journal of Neurology, Neurosurgery, and Psychiatry2(Suppl 2):ii12-ii17. [2]Foundation NB. The essential guide to brain tumors(2007). [3]Institute, National Cancer. Brain tumors(2002). Available from: http://www.cancer.gov/cancertopics/wyntk/brain, [4]Smeltzer SC, Bare GB. Brunner & Suddarth’s textbook of medical-surgical nursing. USA: Lippincott Williams & Wilkins (2005). 1970–1977. [5]Armstrong TS, Gilbert MR. Metastatic brain tumors: diagnosis, treatment, and nursing interventions. Clinical Journal of Oncology Nursing(2000) 4(5):217–225. [6]Fitzsimmons B, Bohan E. Common neurosurgical and neurological disorders Morton PG, Fontaine D, Hudak CM, Gallo BM, editors. USA (2004). 796–838. [7]Hill CI, Nixon CS, Ruehmeier JL, Wolf LM. Brain tumors. Physical Therapy(2002) 82(5):496–502. [8]Smith GB, Schnell S. Nursing care of patients with central nervous system disorders. In: Williams LS, Hopper PD, editors. Understanding Medical Surgical Nursing. USA: Philadelphia: FA. Davis Company (2003). p. 849–851. [9]Boss BJ, Wilkerson RR. Concepts of neurologic dysfunction. In: Huether SE, editor. Understanding Pathophysiology, McKance KL. USA:Philadelphia: Mosby, Inc (2006). p. 491–546. [10]Doolittle ND. State of the science in brain tumor classsification. Seminars in Oncology Nursing(2004) 20(4):224–230. [11]Soffietti R,Rudā R, Mutani R. Management of brain metastases. Journal of Neurology(2002) 249(10):1357–1369. [12]Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. The Lancet. Oncology(2008) 9(9):884–891. [13]Ostrom QT,Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015.
  2. Neuro-oncology(2018) 20(supp_4):iv1-iv86. [14]Tamimi AF, JuweidM. Epidemiology and outcome of glioblastoma. Australia:Brisbane: Codon Publications (2017). 143–153. [15]Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clinical Cancer Research(2013) 19(4):764–772. [16]Louis DN, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee WK. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica(2016) 131(6):803–820. [17]Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous syst